Synthetic mRNA nanoparticle-mediated restoration of p53 tumor suppressor sensitizes p53 -deficient cancers to mTOR inhibition.

Na Kong,Wei Tao,Xiang Ling,Junqing Wang,Yuling Xiao,Sanjun Shi,Xiaoyuan Ji,Aram Shajii,Silvia Tian Gan,Na Yoon Kim,Dan G Duda,Tian Xie,Omid C Farokhzad,Jinjun Shi
DOI: https://doi.org/10.1126/scitranslmed.aaw1565
IF: 17.1
2019-01-01
Science Translational Medicine
Abstract:Loss of function in tumor suppressor genes is commonly associated with the onset/progression of cancer and treatment resistance. The p53 tumor suppressor gene, a master regulator of diverse cellular pathways, is frequently altered in various cancers, for example, in similar to 36% of hepatocellular carcinomas (HCCs) and similar to 68% of non-small cell lung cancers (NSCLC5). Current methods for restoration of p53 expression, including small molecules and DNA therapies, have yielded progressive success, but each has formidable drawbacks. Here, a redox-responsive nanoparticle (NP) platform is engineered for effective delivery of p53-encoding synthetic messenger RNA (mRNA). We demonstrate that the synthetic p53-mRNA NPs markedly delay the growth of p53-null HCC and NSCLC cells by inducing cell cycle arrest and apoptosis. We also reveal that p53 restoration markedly improves the sensitivity of these tumor cells to everolimus, a mammalian target of rapamycin (mTOR) inhibitor that failed to show clinical benefits in advanced HCC and NSCLC. Moreover, cotargeting of tumor-suppressing p53 and tumorigenic mTOR signaling pathways results in marked antitumor effects in vitro and in multiple animal models of HCC and NSCLC. Our findings indicate that restoration of tumor suppressors by the synthetic mRNA NP delivery strategy could be combined together with other therapies for potent combinatorial cancer treatment.
What problem does this paper attempt to address?